Selected research
Industry Research
Inactivated Vaccine Industry Research Report 2026
Market perspective
The global Inactivated Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Inactivated Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Inactivated Vaccine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Inactivated Vaccine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Inactivated Vaccine include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia) and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Inactivated Vaccine market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Inactivated Vaccine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inactivated Vaccine Market by Company
Johnson & Johnson(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
GlaxoSmithKline(U.K.)
Serum Institute of India Pvt(India)
Sanofi Pasteur(France)
MedImmune(U.S.)
Emergent BioSolutions(U.S.)
CSL Limited(Australia)
Astellas Pharma(Japan)
Inactivated Vaccine Segment by Type
Children Inactivated Vaccine
Adult Inactivated Vaccine
Inactivated Vaccine Segment by Application
Hospital
Medical Center
Inactivated Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Inactivated Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Children Inactivated Vaccine
- Adult Inactivated Vaccine
Applications
- Hospital
- Medical Center
Companies covered
- Johnson & Johnson(U.S.)
- Merck & Co(U.S.)
- Pfizer(U.S.)
- GlaxoSmithKline(U.K.)
- Serum Institute of India Pvt(India)
- Sanofi Pasteur(France)
- MedImmune(U.S.)
- Emergent BioSolutions(U.S.)
- CSL Limited(Australia)
- Astellas Pharma(Japan)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Inactivated Vaccine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Children Inactivated Vaccine
- 2.2.3 Adult Inactivated Vaccine
- 2.3 Inactivated Vaccine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Medical Center
- 2.4 Assumptions and Limitations
3 Inactivated Vaccine Breakdown Data by Type
- 3.1 Global Inactivated Vaccine Historic Market Size by Type (2021-2026)
- 3.2 Global Inactivated Vaccine Forecasted Market Size by Type (2027-2032)
4 Inactivated Vaccine Breakdown Data by Application
- 4.1 Global Inactivated Vaccine Historic Market Size by Application (2021-2026)
- 4.2 Global Inactivated Vaccine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Inactivated Vaccine Market Perspective (2021-2032)
- 5.2 Global Inactivated Vaccine Growth Trends by Region
- 5.2.1 Global Inactivated Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Inactivated Vaccine Historic Market Size by Region (2021-2026)
- 5.2.3 Inactivated Vaccine Forecasted Market Size by Region (2027-2032)
- 5.3 Inactivated Vaccine Market Dynamics
- 5.3.1 Inactivated Vaccine Industry Trends
- 5.3.2 Inactivated Vaccine Market Drivers
- 5.3.3 Inactivated Vaccine Market Challenges
- 5.3.4 Inactivated Vaccine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Inactivated Vaccine Players by Revenue
- 6.1.1 Global Top Inactivated Vaccine Players by Revenue (2021-2026)
- 6.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2021-2026)
- 6.2 Global Inactivated Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Inactivated Vaccine Head Office and Area Served
- 6.4 Global Inactivated Vaccine Players, Product Type & Application
- 6.5 Global Inactivated Vaccine Manufacturers Established Date
- 6.6 Global Inactivated Vaccine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Inactivated Vaccine Market Size (2021-2032)
- 7.2 North America Inactivated Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Inactivated Vaccine Market Size by Country (2021-2026)
- 7.4 North America Inactivated Vaccine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Inactivated Vaccine Market Size (2021-2032)
- 8.2 Europe Inactivated Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Inactivated Vaccine Market Size by Country (2021-2026)
- 8.4 Europe Inactivated Vaccine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Inactivated Vaccine Market Size (2021-2032)
- 9.2 Asia-Pacific Inactivated Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Inactivated Vaccine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Inactivated Vaccine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Inactivated Vaccine Market Size (2021-2032)
- 10.2 South America Inactivated Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Inactivated Vaccine Market Size by Country (2021-2026)
- 10.4 South America Inactivated Vaccine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Inactivated Vaccine Market Size (2021-2032)
- 11.2 Middle East & Africa Inactivated Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Inactivated Vaccine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Inactivated Vaccine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Johnson & Johnson(U.S.)
- 12.1.1 Johnson & Johnson(U.S.) Company Information
- 12.1.2 Johnson & Johnson(U.S.) Business Overview
- 12.1.3 Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
- 12.1.5 Johnson & Johnson(U.S.) Recent Developments
- 12.2 Merck & Co(U.S.)
- 12.2.1 Merck & Co(U.S.) Company Information
- 12.2.2 Merck & Co(U.S.) Business Overview
- 12.2.3 Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
- 12.2.5 Merck & Co(U.S.) Recent Developments
- 12.3 Pfizer(U.S.)
- 12.3.1 Pfizer(U.S.) Company Information
- 12.3.2 Pfizer(U.S.) Business Overview
- 12.3.3 Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
- 12.3.5 Pfizer(U.S.) Recent Developments
- 12.4 GlaxoSmithKline(U.K.)
- 12.4.1 GlaxoSmithKline(U.K.) Company Information
- 12.4.2 GlaxoSmithKline(U.K.) Business Overview
- 12.4.3 GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
- 12.4.5 GlaxoSmithKline(U.K.) Recent Developments
- 12.5 Serum Institute of India Pvt(India)
- 12.5.1 Serum Institute of India Pvt(India) Company Information
- 12.5.2 Serum Institute of India Pvt(India) Business Overview
- 12.5.3 Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
- 12.5.5 Serum Institute of India Pvt(India) Recent Developments
- 12.6 Sanofi Pasteur(France)
- 12.6.1 Sanofi Pasteur(France) Company Information
- 12.6.2 Sanofi Pasteur(France) Business Overview
- 12.6.3 Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
- 12.6.5 Sanofi Pasteur(France) Recent Developments
- 12.7 MedImmune(U.S.)
- 12.7.1 MedImmune(U.S.) Company Information
- 12.7.2 MedImmune(U.S.) Business Overview
- 12.7.3 MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
- 12.7.5 MedImmune(U.S.) Recent Developments
- 12.8 Emergent BioSolutions(U.S.)
- 12.8.1 Emergent BioSolutions(U.S.) Company Information
- 12.8.2 Emergent BioSolutions(U.S.) Business Overview
- 12.8.3 Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
- 12.8.5 Emergent BioSolutions(U.S.) Recent Developments
- 12.9 CSL Limited(Australia)
- 12.9.1 CSL Limited(Australia) Company Information
- 12.9.2 CSL Limited(Australia) Business Overview
- 12.9.3 CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
- 12.9.5 CSL Limited(Australia) Recent Developments
- 12.10 Astellas Pharma(Japan)
- 12.10.1 Astellas Pharma(Japan) Company Information
- 12.10.2 Astellas Pharma(Japan) Business Overview
- 12.10.3 Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2021-2026)
- 12.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
- 12.10.5 Astellas Pharma(Japan) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst